Subscribe to RSS



F5 Networks, Inc. (NASDAQ:FFIV) Anticipates Drop For Q2 – FFIV, MSFT, ORCL, BMC, NUAN

The anticipations have plunged for F5 Networks, Inc. (NASDAQ:FFIV)’s Q2 results in the month leading up to the firm’s earnings announcement on today. The consensus analyst predicts has decreased from 98 cents per share to the present anticipates of earnings of 82 cents per share.

The present estimation reflects a 6.8 percent dropped from the year-before quarter, at what time F5 declared earnings of 88 cents a share.

The consensus predicts has dropped in excess of the previous quarter, from 92 cents. The analysts are predicting earnings of $3.62 a share. Revenue is anticipated to be $351.8M for the quarter, 3.6 percent higher than the year-earlier total of $339.6M. The revenue is anticipated to come in at $1.47B for the year.

Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Microsoft Corporation(NASDAQ:MSFT) gain +0.65%, Oracle Corporation(NASDAQ:ORCL) edged up +0.37%, BMC Software, Inc.(NASDAQ:BMC) which also increased +2.79% and Nuance Communications Inc.(NASDAQ:NUAN) closed up +0.94%.

F5 Networks, Inc. (NASDAQ:FFIV) stock’s trade at beginning with a price of $72.20 and in ongoing trading session climbed at a high of $72.64 other than after it traded advanced +0.07% to $72.52.

The stock is going forward its 52 week low with 2.49% and lagging behind from its 52 week high price with -47.82%. FFIV last month stock price volatility remained 2.38%.

FFIV stock institutional ownership remained 96.48% while insider ownership included 0.28%. In its share capital FFIV has 78.59 million outstanding shares among them 78.29 million shares have been floated in market exchange.

Company’s beta coefficient included 1.36. Beta factors measures the amount of market risk associated with market trade.


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

Over-Surged Session Stocks: GW Pharmaceuticals PLC (Nasdaq:GWPH), IntriCon Corp (Nasdaq:IIN), Idera Pharmaceuticals Inc (Nasdaq:IDRA), Intercept Pharmaceuticals Inc (Nasdaq:ICPT), Epizyme Inc (Nasdaq:EPZM)

Over-Surged Session Stocks: GW Pharmaceuticals PLC (Nasdaq:GWPH), IntriCon Corp (Nasdaq:IIN), Idera Pharmaceuticals Inc (Nasdaq:IDRA), Intercept Pharmaceuticals Inc (Nasdaq:ICPT), Epizyme Inc (Nasdaq:EPZM)

Shares of GW Pharmaceuticals plc (Nasdaq:GWPH) are trading on different levels, after research firm Morgan Stanley initiated coverage on the company with an Overweight rating and a price target of $103.00 per share. GWPH stock is currently trading for about $63.61, up $17.57 (or +38.16%), with a volume of 4,988,786 shares traded so far. The

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

Shares of BioFuel Energy Corp. (Nasdaq:BIOF) skyrocketed on Thursday’s market activity, currently trading for about $8.20, up $2.14 (or +35.30%), and 5,845,868 of its shares exchanged hands so far BioFuel Energy recently received a preliminary non-binding proposal, which suggested the company acquire acquire all of the equity interests in real-estate developer JBGL Capital and JBGL

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.